Current Status and Future Challenges of Liquid Biopsy

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 3592

Special Issue Editors


E-Mail Website
Guest Editor
Division of Thoracic Surgery, Department of Surgery, Kindai University School of Medicine, Osakasayama, Japan
Interests: lung cancer; circulating tumor DNA; liquid biopsy; acquired resistance mechanism

E-Mail Website
Guest Editor
Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan
Interests: lung cancer; circulating tumor DNA; liquid biopsy; acquired resistance mechanism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Liquid biopsy is one of the biomarker detection techniques that is expected to expand its clinical applications in the near future. In addition to its role as a genetic test to explore predictive biomarkers for cancer treatment, liquid biopsy can detect minimal residual disease (MRD) after curative-intent treatment, meaning that it can detect disease recurrence prior to radiological examination.

In this Special Issue, we aim to publish recent advances in liquid biopsy from various perspectives, including basic research, translational data, clinical observations and clinical trials, as well as comprehensive reviews that focus on liquid biopsy in cancers, including but not limited to lung cancer, urothelial cancer, renal cell carcinoma, digestive cancer and breast cancer.

This Special Issue will cover all aspects of recent advances in liquid biopsy, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating cell-free RNA, extracellular vesicles, and tumor-educated platelet (TEP). We invite all scientists working in the field of liquid biopsy to participate in this Special Issue. Original research articles, reviews, or short perspective articles on all aspects related to liquid biopsy are welcomed.

Dr. Shuta Ohara
Dr. Kenichi Suda
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liquid biopsy
  • biomarker
  • minimal residual disease (MRD)
  • circulating tumor DNA (ctDNA)
  • tumor-educated platelet (TEP)

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 1898 KiB  
Review
Circulating Tumor DNA in the Management of Early-Stage Breast Cancer
by Katerina Vlataki, Sevastiani Antonouli, Christina Kalyvioti, Evangeli Lampri, Sevasti Kamina, Davide Mauri, Haralampos V. Harissis and Angeliki Magklara
Cells 2023, 12(12), 1573; https://doi.org/10.3390/cells12121573 - 7 Jun 2023
Cited by 5 | Viewed by 3135
Abstract
Liquid biopsies refer to the isolation and analysis of tumor-derived biological material from body fluids, most commonly blood, in order to provide clinically valuable information for the management of cancer patients. Their non-invasive nature allows to overcome the limitations of tissue biopsy and [...] Read more.
Liquid biopsies refer to the isolation and analysis of tumor-derived biological material from body fluids, most commonly blood, in order to provide clinically valuable information for the management of cancer patients. Their non-invasive nature allows to overcome the limitations of tissue biopsy and complement the latter in guiding therapeutic decision-making. In the past years, several studies have demonstrated that circulating tumor DNA (ctDNA) detection can be used in the clinical setting to improve patient prognosis and monitor therapy response, especially in metastatic cancers. With the advent of significant technological advances in assay development, ctDNA can now be accurately and reliably identified in early-stage cancers despite its low levels in the bloodstream. In this review, we discuss the most important studies that highlight the potential clinical utility of ctDNA in early-stage breast cancer focusing on early diagnosis, detection of minimal residual disease and prediction of metastatic relapse. We also offer a concise description of the most sensitive techniques that are deemed appropriate for ctDNA detection in early-stage cancer and we examine their advantages and disadvantages, as they have been employed in various studies. Finally, we discuss future perspectives on how ctDNA could be better integrated into the everyday oncology practice. Full article
(This article belongs to the Special Issue Current Status and Future Challenges of Liquid Biopsy)
Show Figures

Figure 1

Back to TopTop